EnteroMedics (ETRM) tanks in after hours trading after its electric shock device for weight-loss failed to meet its key goal in clinical trials. The goal was to help patients lose 10% more of their excess weight than patients implanted with a nonworking, or "sham," device. The 10% threshold was agreed upon by the company to meet the FDA's request that the device show " super superiority." However, the company says it still plans to forge ahead with seeking regulatory approval. Shares -50% AH.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs